Clinical Trials · NCT05659537
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 212
- Start date
- Dec 2022
- Locations
- 7 sites, India
- Primary endpoint
- Number of Participants With One or More Adverse Events (AEs) - Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Deaths